Mavefund EN
Co-Diagnostics Inc logo

Co-Diagnostics Inc

CODX
Letzter Kurs (USD) US$1.23
Marktkapitalisierung (USD) US$4.5m
Kursänderung 12 Monate N/A
Loading the 12-month Mave Thesis and 1-month news signal

Start Heute Aktien Watchlist

Co-Diagnostics Inc Überblick

Branche: Medical Devices

Sektor: Healthcare

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tes

Research-Überblick

Letztes Berichtsdatum 2026-08-13

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Co-Diagnostics Inc (CODX): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
CODX · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Medical Devices
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-13
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Co-Diagnostics Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 13, 2026

Quarterly result summary

Revenue was $0.2M (+6% YoY). Net loss was -$6.3M.

Revenue $0.2M +6% YoY
Net loss -$6.3M reported

Was sich verändert hat

  • Revenue +6% YoY to $0.2M.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 1.00/5
Co-Diagnostics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

Eigenkapitalrendite

Score 1.83/5
Co-Diagnostics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Co-Diagnosti... CODX US$4.5m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 1.16/5
Co-Diagnostics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Co-Diagnosti... CODX US$4.5m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

Verschuldung

Score 3.70/5
Co-Diagnostics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Co-Diagnosti... CODX US$4.5m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Co-Diagnostics Inc logo

Co-Diagnostics Inc

US$1.23

US$4.5m

0.00%

N/A